The Exchange has sought clarification from AstraZeneca Pharma India Limited with respect to recent news item captioned Trump Tariff News Live: GSK and AstraZeneca among top companies told to 'cut US prices or else'. The response from the Company is attached.

Regulatory & Legal View source PDF Explain this filing

ASTRAZEN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.5%Reaction day

₹8909.50

prior close

₹8909.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.5%-0.1% vs market

Pharmaceuticals peers, median of 150sector+0.7%-0.2% vs sector

On the reaction day the stock moved 0.1 pts less than Nifty Microcap 250 and 0.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

+0.2

15m

+0.1

30m

-0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.5+0.5-0.1+0.7-0.2

Next day

-0.7+0.2-0.9-0.2-0.5

-0.8-0.9+0.1-1.9+1.1

-2.3-1.2-1.1-1.1-1.2

-2.0-2.0+0.1-2.0+0.0

-0.6-1.9+1.2-1.6+1.0

-5.4-1.2-4.2-1.0-4.4

15d

-9.6-1.5-8.1-2.3-7.3

+1.9+0.0+1.8-1.9+3.7

+5.3-0.5+5.7-3.9+9.1

+7.8+1.3+6.5-3.2+11.0

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 150Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The BSE and NSE asked AstraZeneca Pharma India to clarify a MoneyControl news item headlined 'Trump Tariff News Live: GSK and AstraZeneca among top companies told to cut US prices or else.' The company clarified that (a) no negotiations were taking place in relation to the article, (b) it is not aware of any undisclosed information that could materially impact its share price, and (c) there are no regulatory or legal proceedings on this matter. Importantly, the company stated that the news item does not pertain to AstraZeneca Pharma India Limited (the Indian listed entity) and likely refers to its global parent AstraZeneca. No financial figures or material impact details were disclosed.

Likely market impact

This clarification removes short-term uncertainty for retail investors — the US pricing pressure story relates to the global parent, not the Indian listed subsidiary, and the company confirms no direct exposure or undisclosed developments. Stock price reaction should be neutral, as the clarification addresses the misinformation rather than introducing new information.